Apogee Therapeutics announced on Monday a positive outlook for its anticipated competitor to the eczema medication, Dupixent, describing it as a "best case scenario." This development caused Apogee's stock to rise by 20%. The company is preparing to challenge the eczema drug market dominated by Regeneron with its new product.